This post-hoc analysis of 2 randomized trials of the once weekly glucagon-like peptide-1 receptor agonist dulaglutide (DU) assessed the proportion of Chinese patients with type 2 diabetes (T2D) achieving a composite endpoint of glycated hemoglobin (A1C) <7.0%, no weight gain (≤0 kg), and no hypoglycemia (confirmed glucose ≤3.9 mmol/L or report of severe hypoglycemia) after 26 or 52 weeks of treatment with DU 1.5 mg or 0.75 mg vs. glimepiride (GLIM) or insulin glargine (GLAR). Patients in the DU vs. GLIM study (n = 556) were treatment-naive or discontinued from oral monotherapy; those in the DU vs. GLAR study (n = 591) continued on metformin and/or sulfonylurea. Analyses in each trial were on modified intent—to-treat population; missing values were imputed using last observation carried forward. Significantly (p<.001, Fisher’s exact test) more patients achieved the composite endpoint with DU 1.5 mg or 0.75 mg vs. GLIM after 26 weeks (47.8% and 39.2% vs. 19.9%), as well as vs. GLAR after 26 weeks (39.5% and 30.1% vs. 14.9%) and after 52 weeks (26.0% and 23.0% vs. 6.7%). Similar results were observed for composite endpoints of A1C <7.0% and no weight gain, and A1C <7.0% and no hypoglycemia. Dulaglutide is an effective treatment option for Chinese patients with T2D, resulting in a large proportion of patients reaching A1C targets without weight gain or hypoglycemia.
X. Xiao: None. C. Wang: None. F. Wang: None. P. Li: Employee; Self; Eli Lilly and Company. L. Gu: Employee; Self; Eli Lilly and Company.
